News

The licence will enable other companies and organisations to re-formulate and manufacture specially designed LPV/r and r paediatric treatments for distribution in low- and middle-income countries where 99%

The sBLA was based on an international, multi-center, double-blind, randomized, placebo-controlled Phase III trial which included around 250 adult patients with upper limb spasticity. The trial, which was

As part of the deal, UCB will manufacture and supply the product for commercialisation and Daiichi will manage the distribution and book sales. The deal, which is subject

Under the five-year deal, Cancer Research UK researchers will have access to around two million molecules in AstraZeneca’s compound library, in addition to screening tools at the facility

The accelerated review procedure is granted infrequently by the EMA and so far it has not been awarded in the cardiovascular area. The decision on European Union (EU)

Actavis has begun shipping the product and, under applicable Hatch Waxman rules, is entitled to 180 days of marketing exclusivity. Intuniv is a prescription medicine used to treat

The grants awarded through the Foundation’s landmark Secure the Future initiative, which this year celebrates its 15th anniversary of providing community-based care and support to people living with

Teva was first to file, opening the generic market for the product, as well as making the product eligible for 180 days of marketing exclusivity. Exforge HCT (Amlodipine,

The IND filing for minocycline gel is part of the company’s strategy to develop improved drug delivery options for established drugs. Minocycline gel is a new formulation using